[Porphyria cutanea tarda和C型肝炎的感染] 这种疾病的发病率很高
Anne Stockmann1, Anne Lindegaard Christiansen2,3, Henrik Frank Lorentzen1
1Hudafdeling I og Allergicentret, Odense Universitetshospital.
Ugeskrift for laeger
|September 30, 2025
概括
针对型肝炎 (HCV) 感染的直接作用抗病毒药物可以导致皮质迟症 (PCT) 的缓解. 在PCT患者中治疗HCV对于管理这种皮肤疾病至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 皮肤病学 皮肤病学
- 病毒学 病毒学
背景情况:
- 皮性迟 (PCT) 是一种光敏感性疾病.
- 肝炎C病毒 (HCV) 感染是PCT的已知原因之一.
- 标准的PCT治疗包括静脉切割和氧化.
研究的目的:
- 在HCV治疗后报告PCT解决的病例.
- 为了突出HCV和PCT之间的联系.
- 强调HCV查在PCT患者中的重要性.
主要方法:
- 两例病例报告的女性 (82岁和60岁) 与PCT继发于HCV.
- 同时治疗PCT与静脉切割和氧化.
- 使用glecaprevir/pibrentasvir治疗HCV的方法.
主要成果:
- 在这两位患者中成功根除了HCV感染.
- 在两名患者中都实现了PCT的长期缓解.
- 在管理与HCV相关的PCT方面证明了直接作用抗病毒药物的有效性.
结论:
- 对PCT患者进行HCV查至关重要.
- 治疗潜在的HCV感染可以诱导PCT缓解.
- 直接作用的抗病毒疗法为与HCV相关的PCT提供了可行的治疗方法.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
157
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
157
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
193
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
193
Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Pulmonary Tuberculosis I
800
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
800
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
179
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
179
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234


